Safety and effectiveness of rheosorbilact detoxification therapy in stage 1–3 CKD

Main Article Content

D.D. Ivanov

Abstract

The problem of detoxification therapy, in particular for kidney disease, is an important component of modern treatment. Renal dysfunction significantly complicates detoxification measures for at least two reasons. The first is to reduce the clearance of toxic substances, increase their content and redistribution in body tissues while reducing the glomerular filtration rate. The second reason is a change in the pharmacodynamics of detoxification drugs due to decreased renal function. Rheosorbilact is a hyperosmolar crystalloid electrolyte solution for infusion, which has detoxifying, rheological and alkalizing action with stimulation of intestinal motility. The drug is used to correct metabolic acidosis without causing sharp fluctuations in pH, due to the sodium lactate content, the effect of which manifested itself in 20–30 minutes after administration. Another important component of the drug is sorbitol, which in the form of an isotonic solution has a disaggregating effect, improving microcirculation and tissue perfusion. Sodium chloride in the drug replenishes the deficiency of sodium and chlorine ions, performing a rehydrating effect and increasing the volume of circulating blood, increasing diuresis, and calcium chloride replenishes the deficiency of calcium ions, reducing the permeability of the vascular wall and thus preventing the development of inflammatory reactions. The article presents a detailed analysis of the use of rheosorbilact with an emphasis on kidney disease and their function. Rheosorbilact can be used effectively and safely at a dose of 200 ml at a body weight of less than 60 kg and up to 400 ml at a body weight of more than 60 kg twice a day at an estimated glomerular filtration rate of more than 45 ml/min/m2 and no decompensated heart failure and stage III hypertension.

Article Details

How to Cite
Ivanov, D. “Safety and Effectiveness of Rheosorbilact Detoxification Therapy in Stage 1–3 CKD”. KIDNEYS, vol. 10, no. 2, Aug. 2021, pp. 65-69, doi:10.22141/2307-1257.10.2.2021.234321.
Section
To Help the Practitioner

References

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Chapter 1: Introduction. Kidney Inter Suppl. 2012;2(2):156-152.

Xie Y, Bowe B, Mokdad AH, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018 Sep;94(3):567-581. doi:10.1016/j.kint.2018.04.011.

Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014 May;63(5):789-797. doi:10.1053/j.ajkd.2013.12.012.

Yamada Y, Ikenoue T, Saito Y, Fukuma S. Undiagnosed and untreated chronic kidney disease and its impact on renal outcomes in the Japanese middle-aged general population. J Epidemiol Community Health. 2019 Dec;73(12):1122-1127. doi:10.1136/jech-2019-212858.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl. 2013;3(1):1-150.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Inter Suppl. 2012;2(1):1-138.

Pyrig LA, Ivanov DD, Taran OI, et al., authors; Pyrig LA, Ivanov DD, editors. Nefrologija: nacional'nyj pidruchnyk [Nephrology: national textbook]. Donetsk: Publisher Zaslavsky OYu; 2014. 316 p. (in Ukrainian).

Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol. 2010 Sep;6(9):521-529. doi:10.1038/nrneph.2010.100.

Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int. 2009 Aug;76(4):422-427. doi:10.1038/ki.2009.159.

Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care. 2008;12(3):R74. doi:10.1186/cc6916.

Ivanova MD, Gozhenko AI, Crestanello T, Ivanov DD. Early Coaching to Increase Water Intake in CKD. Ann Nutr Metab. 2020;76(Suppl 1):69-70. doi:10.1159/000515276.

Ivanov D, Savytska L, Kulachek V. The association of kidney stress test with water salt loading with estimated glomerular filtration rate decline in patients with chronic kidney disease stage 1-3. Arch Balk Med Union. Sept 2019;54(3):11-17. doi:10.31688/ABMU.2019.54.3.06.

Clark WF, Sontrop JM, Huang SH, et al. Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease: The CKD WIT randomized clinical trial. JAMA. 2018 May 8;319(18):1870-1879. doi:10.1001/jama.2018.4930.

Ivanov DD, Ivanova MD. Hydration: the review of 3 trials. Počki. 2020;9(1):10-13. doi:10.22141/2307-1257.9.1.2020.196911.

Wagner S, Merkling T, Metzger M, et al. Water intake and progression of chronic kidney disease: the CKD-REIN cohort study. Nephrol Dial Transplant. 2021 Feb 12:gfab036. doi:10.1093/ndt/gfab036.

Krasyuk EK, Moyseyenko VA, Nykula TD, Palamar BI. Influence Reosorbilact on cardiohemodynamics and microcirculation parameters at the patients with chronic kidney disease. Ukrainian Chemotherapeutic Journal. 2008;(22):25. (in Ukrainian).

Instructions for use Reosorbilact. Available from: https://mozdocs.kiev.ua/likiview.php?id=14632.

Chistik T. Multicenter randomized trial Rheostat - study of the efficacy and safety of using the drug Rheosorbilact in patients with various nosologies accompanied by endogenous intoxication syndrome. Novosti Meditsiny i Farmatsii. 2019;(678):6-8. (in Russian).

Nikonov VV, Lyzohub KI, Lyzohub MV. Infusion therapy for pneumonia: what's new? Medicina neotložnyh sostoânij. 2020;16(2):31-36. doi:10.22141/2224-0586.16.2.2020.203138. (in Ukrainian).

Myhajlovs'ka NS, Lisova OO, Minjajlenko LJe. Algorytm dijal'nosti simejnogo likarja pry osnovnyh zahvorjuvannjah sechovydil'noi' systemy: navchal'no-metodychnyj posibnyk [Algorithm of the family doctor's activity in case of major diseases of the urinary system: teaching guide]. Zaporizhzhia: ZDMU; 2018. 148 p. (in Ukrainian).

International Congress on Infusion Therapy. Resolution and video of the teleconference Infusion Therapy School. Available from: https://infusiontherapy.org/en/news/resolution-and-video-of-the-teleconference-infusion-therapy-school--p441. Accessed: March 30, 2021. (in Ukrainian).

Savokhina MV. Intravenous fluids in the pathogenetic therapy of patients with chronic pyelonephritis. Ukrainian Chemotherapeutic Journal. 2012;(26):217-220. (in Russian).

Fomina SP. Urinary tract infection in children: the clinical protocol draft. Ukrainian Journal of Nephrology and Dialysis. 2017;(56):48-67. doi:10.31450/ukrjnd.4(56).2017.05. (in Ukrainian).

Reosorbilact. Available from: https://compendium.com.ua/dec/267128/. Accessed: May 30, 2021. (in Ukrainian).

Moroz LV, Kul'chak OI, Chyshkevych IV. Efficacy of combination therapy with Xavron, Tivorel and Reosorbilact in patients with pneumonia caused by COVID-19: clinical cases. Novosti Meditsiny i Farmatsii. 2021;(745):6-11. (in Ukrainian).

Orbegozo D, Vincent JL, Creteur J, Su F. Hypertonic Saline in Human Sepsis: A Systematic Review of Randomized Controlled Trials. Anesth Analg. 2019 Jun;128(6):1175-1184. doi:10.1213/ANE.0000000000003955.

Konovchuk VM, Andrushchak AV. The effect of Reosorbilact on volumetric and osmoregulatory renal functions in patients with dopamine-dependent compensation for sepsis-induced hypotension. J Educ Health Sport. 2018;8(2):280-289. doi:10.5281/zenodo.1186275.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>